https://doi.org/10.4081/hmr.v2i7.408

Practical issues involved with the use of bortezomib

Vol. 2 No. 7: New Insights in Hematology, Venice (Italy), May 14-17, 2006
Published: June 8, 2009
Abstract Views: 144
PDF: 147
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

S Lonial
support@pagepress.org
The use of proteasome inhibition as a therapeutic target against human cancers represents an exciting new target either alone, or in combination with other agents. The use of single agent bortezomib in relapsed myeloma resulted in a 43% response rate, improved time to progression, and superior overall survival when compared with high dose dexamethasone in the randomized phase III APEX trial. This survival benefit continues to hold despite the cross-over use of bortezomib for patients initially randomized to receive dexamethasone, further solidifying the use of bortezomib as a standard approach for the management of relapsed myeloma.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Lonial, S. (2009). Practical issues involved with the use of bortezomib. Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.408
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).